is a confidential
first-line resource for early detection of potential impairment in physicians and other licensed health care professionals who suffer from potentially impairing conditions such as substance use disorders. The MPHP coordinates effective detection, evaluation, treatment, and aftercare monitoring of addictive disorders and other psychiatric illnesses. We also assist professionals with disruptive behavioral problems and other conditions such as physical disability or deterioration through the process of aging. Our primary focus is on intervention and recovery, with long-term, intensive monitoring. The anonymity of our program encourages self-referrals and early intervention, which protects patients and saves our participants’ careers. Additionally, participants in the program benefit from advocacy for malpractice insurance carriers, hospitals, and licensure boards. The MPHP
is a confidential
first-line resource for physicians and other licensed health-care professionals who suffer from potentially impairing conditions such as substance-use disorders. The MPHP coordinates effective detection, evaluation, treatment, and aftercare monitoring of physicians with addictive disorders and other psychiatric illnesses. Our primary focus is on intervention and recovery, with long-term, intensive monitoring.The pyrrolidinophenone-type designer drug 4′-methyl-alpha-pyrrolidinohexanophenone (MPHP) is presumed to be a potent psychostimulant as the structurally related drug pyrovalerone. This ishttps://researchemvendor.com
the first report of an acute poisoning involving MPHP.
A 27 year old man was admitted to hospital in an agitated state and with fractures of both feet after jumping from a window. He had reportedly snorted a powder supposed to be cocaine on the previous day and taken amyl nitrite several days before. He presented with pronounced rhabdomyolysis and had to be treated by repeated hemodialysis. Elevated liver parameters indicated toxic liver damage. TOXICOLOGICAL ANALYSIS: The presumed cocaine powder was analyzed by gas chromatography-mass spectrometry (GC-MS) and high-performance liquid chromatography with diode array detection. The liquid and the urine samples were analyzed by headspace gas chromatography with flame ionization detection. Urine was submitted to enzymatic conjugate cleavage and further worked up by liquid-liquid extraction and acetylation or by mixed-mode solid-phase extraction (SPE) and trimethylsilylation. Serum was worked up by mixed-mode SPE. All extracts were analyzed by fullscan GC-MS. The powder and liquid were identified as MPHP
and amyl nitrite, respectively. In the serum sample, MPHP
was found in a concentration of approximately 100 ng/ml, while its 4′-carboxy metabolite was detected in urine. Amyl nitrite was not found in urine. The use of MPHP instead of cocaine is in line with its presumed stimulant properties. The presented data indicate that it can lead to serious poisoning with toxic liver damage and rhabdomyolysis.
is a drug that presumably acts as a potent agonist for the cannabinoid receptors. It had never previously been reported in the scientific or patent literature, and was first identified by laboratories in the Netherlands and Germany in June 2011 as an ingredient in synthetic cannabis smoking blends.
AM2201 (Item No. 10707) is a potent synthetic cannabinoid (CB) which binds the CB1 and CB2 receptors with high affinity (Ki = 1.0 and 2.6 nM, respectively). MAM-2201 is an analog of AM2201 that is methylated at the 4 position of the naphthyl group. The physiological and toxicological properties of this compound have not been delineated. This product is intended for research and forensic purposes.
This product is a qualified Reference Material (RM) that has been
manufactured and tested to meet ISO17025 and Guide 34 guidelines. These
materials are tested using validated analytical methods on qualified
instrumentation to ensure traceability of measurements. All traceable
RMs may be distinguished by their CofAs and can be downloaded below
using the batch number located on the product label. For a
representative CofA please contact our technical support.
Herbal products containing synthetic cannabinoids-initially sold as legal alternatives to marijuana-have become major drugs of abuse. Among the synthetic cannabinoids, [1-(5-fluoropentyl)-1H-indol-3-yl](4-methyl-1-naphthalenyl)-methanone (MAM-2201) has been recently detected in herbal products and has psychoactive and intoxicating effects in humans, suggesting that MAM-2201 alters brain function. Nevertheless, the pharmacological actions of MAM-2201 on cannabinoid receptor type 1 (CB1R) and neuronal functions have not been elucidated. We found that MAM-2201 acted as an agonist of human CB1Rs expressed in AtT-20 cells. In whole-cell patch-clamp recordings made from Purkinje cells (PCs) in slice preparations of the mouse cerebellum, we also found that MAM-2201 inhibited glutamate release at parallel fiber-PC synapses via activation of presynaptic CB1Rs. MAM-.